Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)

INTRODUCTION: Although dimethyl fumarate (DMF) has been approved since 2017 for treatment of moderate-to-severe plaque psoriasis, limited data on its safety and efficacy are available in clinical practice. The objective was to assess the efficacy and safety of DMF in patients with moderate-to-severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Daudén, Esteban, de la Cueva, Pablo, Salgado-Boquete, Laura, Llamas-Velasco, Mar, Fonseca, Eduardo, Pau-Charles, Ignasi, Asensio, David, Guilà, Meritxell, Carrascosa, José Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823187/
https://www.ncbi.nlm.nih.gov/pubmed/36456890
http://dx.doi.org/10.1007/s13555-022-00863-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823187/
https://www.ncbi.nlm.nih.gov/pubmed/36456890
http://dx.doi.org/10.1007/s13555-022-00863-2

Ejemplares similares